[go: up one dir, main page]

ZA965368B - A pharmaceutical formulation - Google Patents

A pharmaceutical formulation

Info

Publication number
ZA965368B
ZA965368B ZA965368A ZA965368A ZA965368B ZA 965368 B ZA965368 B ZA 965368B ZA 965368 A ZA965368 A ZA 965368A ZA 965368 A ZA965368 A ZA 965368A ZA 965368 B ZA965368 B ZA 965368B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
ZA965368A
Other languages
English (en)
Inventor
Thorkild Christensen
Per Balschmidt
Hans Holmega Soerensen
Ole Hvilsted Olsen
Lars Thim
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA965368B publication Critical patent/ZA965368B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA965368A 1995-07-14 1996-06-25 A pharmaceutical formulation ZA965368B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US119395P 1995-07-14 1995-07-14

Publications (1)

Publication Number Publication Date
ZA965368B true ZA965368B (en) 1997-01-14

Family

ID=21694837

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965368A ZA965368B (en) 1995-07-14 1996-06-25 A pharmaceutical formulation

Country Status (14)

Country Link
EP (1) EP0839049A1 (fr)
JP (1) JPH11509212A (fr)
KR (1) KR19990028981A (fr)
CN (1) CN1190897A (fr)
AU (1) AU715997B2 (fr)
BR (1) BR9609741A (fr)
CA (1) CA2226523A1 (fr)
CZ (1) CZ9498A3 (fr)
HU (1) HUP9802287A3 (fr)
IL (1) IL122583A0 (fr)
NO (1) NO980155D0 (fr)
PL (1) PL324379A1 (fr)
WO (1) WO1997003692A1 (fr)
ZA (1) ZA965368B (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69719367T2 (de) * 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP2050762A3 (fr) 1998-03-10 2009-07-08 Genentech, Inc. Nouvelles polypeptides et acides nucléiques les codant
EP3112468A1 (fr) 1998-05-15 2017-01-04 Genentech, Inc. Polypeptides allogéniques il-17 et utilisations thérapeutiques
EP2333069A3 (fr) 1998-05-15 2011-09-14 Genentech, Inc. Utilisations therapeutiques de polypeptides homologues de il-17
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1956030B1 (fr) 1999-06-15 2009-11-11 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP1690873A3 (fr) 1999-12-01 2006-08-23 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
EP2258848B1 (fr) 1999-12-23 2014-03-05 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
AU785055B2 (en) 2000-01-13 2006-09-07 Genentech Inc. Novel stra6 polypeptides
KR100890679B1 (ko) 2000-02-24 2009-03-26 일라이 릴리 앤드 캄파니 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
EP1265630B1 (fr) 2000-03-24 2006-06-07 Genentech, Inc. Utilisation de l'insuline pour traiter des affections des cartilages
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
WO2002011695A2 (fr) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
EP2014298A3 (fr) 2000-08-24 2009-10-07 Genentech, Inc. Polypeptides d'interleukine-22, acides nucléiques les codant et procédés de traitement des troubles pancréatiques
EP1944317A3 (fr) 2000-09-01 2008-09-17 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1485477B1 (fr) 2002-02-25 2009-05-13 Genentech, Inc. Nouveau recepteur glm-r de cytokine de type 1
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
CA2528343A1 (fr) 2003-06-06 2005-01-06 Genentech, Inc. Modulation de l'interaction chaine hgf beta/c-met
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
CA2561577A1 (fr) 2004-03-30 2005-10-13 Nsgene A/S Utilisation therapeutique d'un facteur de croissance, nsg33
US7264314B2 (en) 2004-10-27 2007-09-04 Brennan Miles B Adrenocorticotropic hormone analogs and related methods
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
WO2008018854A2 (fr) 2005-06-06 2008-02-14 The Rockefeller University Lysines bactériophages pour le bacillus anthracis
PT1899378E (pt) 2005-06-21 2010-01-26 Xoma Technology Ltd Anticorpos de ligação de il-1β e os seus fragmentos
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ATE491026T1 (de) 2005-08-24 2010-12-15 Univ Rockefeller Ply-gbs-lysinmutanten
EP1962584A2 (fr) 2005-11-21 2008-09-03 Genentech, Inc. Nouvelles dissociations de gènes, compositions et procédés les concernant
CA2633554C (fr) 2005-12-22 2012-11-13 Genetech, Inc. Production recombinante de proteines de liaison d'heparine
CA2651793C (fr) 2006-02-02 2015-07-07 Trimeris, Inc. Peptides inhibiteurs de fusion du vih a proprietes biologiques ameliorees
WO2007114979A2 (fr) 2006-02-17 2007-10-11 Genentech, Inc. Nouvelles disruption géniques, compositions et procédés associés
EP2389948A1 (fr) 2006-03-23 2011-11-30 Novartis AG Thérapeutique anticorps antigène de cellules anti-tumorales
JP5290148B2 (ja) 2006-04-10 2013-09-18 ジェネンテック, インコーポレイテッド Disheveled(Dvl)PDZ修飾因子
EP2082645A1 (fr) 2006-04-19 2009-07-29 Genentech, Inc. Nouvelle dislocation de gènes, compositions et procédés correspondants
EP2049148B1 (fr) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. Formulation liquide stable à base d'hormone de croissance humaine
WO2008077145A2 (fr) 2006-12-20 2008-06-26 Xoma Technology Ltd. Procédés de traitement de maladies associées à il-1β
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 白介素-22在治疗脂肪肝中的应用
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
NZ591713A (en) * 2008-08-15 2013-07-26 Ironwood Pharmaceuticals Inc Solid stable formulations of linaclotide for oral administration
WO2010027404A2 (fr) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Formulation solide stable de polypeptides thérapeutiques se prêtant à une administration par voie orale
CA2770077A1 (fr) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprenant du linaclotide
KR101952453B1 (ko) 2009-10-15 2019-02-26 제넨테크, 인크. 수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
PH12012501252A1 (en) 2009-12-21 2012-11-05 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CA2787208C (fr) 2010-01-15 2017-06-06 University Of Medicine And Dentistry Of New Jersey Utilisation de composes de vanadium pour accelerer la guerison osseuse
CA2790213A1 (fr) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
CA3027749A1 (fr) 2010-03-22 2011-09-29 Junyan Ji Compositions et procedes utiles pour stabiliser les formulations contenant des proteines
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック, インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
SI2585045T1 (sl) 2010-06-24 2019-11-29 Hoffmann La Roche Sestavki in postopki, ki vsebujejo alkilglikozide za stabilizacijo formulacij, ki vsebujejo beljakovine
PT2603232T (pt) 2010-08-11 2020-01-09 Ironwood Pharmaceuticals Inc Formulações estáveis de linaclotida
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术(上海)有限公司 白介素-22在治疗病毒性肝炎中的应用
AU2011307488B2 (en) 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US9345764B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
JP5913326B2 (ja) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー,リミテッド モエシン断片の診断的および治療的使用
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2012167271A1 (fr) * 2011-06-02 2012-12-06 Baxter International Inc. Formulations de furine recombinante
ES2614864T3 (es) 2011-08-17 2017-06-02 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos gastrointestinales
MX363226B (es) 2011-10-31 2019-03-15 Genentech Inc Formulaciones de anticuerpos.
EP2794657B1 (fr) 2011-12-19 2017-10-11 Xoma (Us) Llc Méthodes de traitement de l'acné
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
EP2802601B1 (fr) 2012-01-09 2019-11-13 The Scripps Research Institute Anticorps humanisés à cdr3 ultralongues
ES2835716T3 (es) 2013-03-15 2021-06-23 Beth Israel Deaconess Medical Ct Inc Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
CA2927543C (fr) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Commutateurs de cellules t a recepteur d'antigene chimere peptidique et leurs utilisations
US20150238631A1 (en) 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016154621A1 (fr) 2015-03-26 2016-09-29 The California Institute For Biomedical Research Récepteurs chimériques non-scfv commutables, commutateurs, et leurs utilisations
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3310376A4 (fr) 2015-06-17 2019-01-23 The California Institute for Biomedical Research Agents thérapeutiques modifiés et compositions associées
EP3442562B1 (fr) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Un dimère il-22 pour l'utilisation dans le traitement de l'entérocolite nécrosante
EP4559928A2 (fr) 2016-10-19 2025-05-28 The Scripps Research Institute Commutateurs de cellules effectrices de récepteur d'antigène chimérique avec fractions de ciblage humanisées et/ou domaines d'interaction de récepteur d'antigène chimérique
AR118536A1 (es) 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
TWI883032B (zh) 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
JP2022554187A (ja) 2019-10-24 2022-12-28 ミノトール セラピューティクス インコーポレイテッド キメラサイトカイン改変抗体およびその使用方法
WO2022232321A1 (fr) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Anticorps bovins chimères humanisés et procédés d'utilisation
CA3217602A1 (fr) 2021-05-06 2022-11-10 Kenneth Petersen Prevention et traitement de la douleur neuropathique induite par une chimiotherapie
WO2022257979A1 (fr) 2021-06-09 2022-12-15 The Scripps Research Institute Conjugués peptidiques double gip/glp-1 à action prolongée et procédés d'utilisation
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain
WO2023212483A1 (fr) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. Méthodes et compositions pour le traitement de maladies et de troubles à éosinophiles
WO2025076280A1 (fr) 2023-10-05 2025-04-10 Ashibio, Inc. Méthodes et compositions de traitement de troubles médiés par la mmp-9

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations

Also Published As

Publication number Publication date
EP0839049A1 (fr) 1998-05-06
CZ9498A3 (cs) 1998-06-17
NO980155L (no) 1998-01-13
CN1190897A (zh) 1998-08-19
HUP9802287A2 (hu) 1999-02-01
MX9800358A (es) 1998-07-31
PL324379A1 (en) 1998-05-25
AU6353496A (en) 1997-02-18
CA2226523A1 (fr) 1997-02-06
KR19990028981A (ko) 1999-04-15
AU715997B2 (en) 2000-02-17
BR9609741A (pt) 1999-03-16
NO980155D0 (no) 1998-01-13
HUP9802287A3 (en) 2000-10-30
IL122583A0 (en) 1998-06-15
JPH11509212A (ja) 1999-08-17
WO1997003692A1 (fr) 1997-02-06

Similar Documents

Publication Publication Date Title
ZA965368B (en) A pharmaceutical formulation
ZA96124B (en) A pharmaceutical formulation
GB9519363D0 (en) Pharmaceutical formulation
EG23826A (en) Pharmaceutical formulations
GB9523752D0 (en) Pharmaceutical formulations
EP0862431A4 (fr) Preparation pharmaceutique
GB9407386D0 (en) Pharmaceutical formulation
GB9402203D0 (en) Pharmaceutical formulation
IL112521A0 (en) Pharmaceutical formulation
ZA958606B (en) A pharmaceutical formulation
GB9405856D0 (en) Pharmaceutical formulation
GB9416599D0 (en) Pharmaceutical formulation
GB9523566D0 (en) Pharmaceutical formulation
ZA96526B (en) Novel pharmaceutical formulation
AU3949093A (en) A pharmaceutical formulation
ZA964372B (en) A pharmaceutical formulation
ZA965367B (en) A pharmaceutical formulation
AP9801196A0 (en) Pharmaceutical preparation
HU9603498D0 (en) Pharmaceutical compounds
ZA96122B (en) A pharmaceutical formulation
ZA96392B (en) Pharmaceutical formulations
ZA96123B (en) A pharmaceutical formulation
GB9500978D0 (en) Pharmaceutical formulations
GB9525386D0 (en) Pharmaceutical formulation
GB9502786D0 (en) Pharmaceutical formulation